Corcept Therapeutics Incorporated Total Liabilities
Corcept Therapeutics Incorporated total liabilities. Based on the latest financial reports, Corcept Therapeutics Incorporated (CORT) has total liabilities worth $176.89 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Corcept Therapeutics Incorporated (CORT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Corcept Therapeutics Incorporated (2000–2025)
Total liabilities of Corcept Therapeutics Incorporated from 2000 to 2025. This chart illustrates how Corcept Therapeutics Incorporated's total liabilities have evolved over time, based on quarterly financial data. Explore Corcept Therapeutics Incorporated strategic investment ratio to see how much of total assets are deployed in long-term investments.
Corcept Therapeutics Incorporated Competitors by Total Liabilities
The table below lists competitors of Corcept Therapeutics Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yunnan Chihong Zinc&Germanium Co Ltd
SHG:600497
|
China | CN¥7.60 Billion |
|
Ultrapar Participações S.A
F:UGR
|
Germany | €31.62 Billion |
|
Atlantic Union Bankshares Corp
NYSE:AUB
|
USA | $32.95 Billion |
|
Strathcona Resources Ltd.
TO:SCR
|
Canada | CA$4.41 Billion |
|
Blackstone Secured Lending Fund
NYSE:BXSL
|
USA | $7.85 Billion |
|
Engie Brasil Energia S.A
F:7TE1
|
Germany | €43.90 Billion |
|
BRF S.A
SA:BRFS3
|
Brazil | R$46.19 Billion |
|
Yunnan Tin Co Ltd
SHE:000960
|
China | CN¥15.59 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Corcept Therapeutics Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Corcept Therapeutics Incorporated asset portfolio.
Liquidity & Leverage Metrics
Corcept Therapeutics Incorporated Total Liabilities Ratios Explained
Corcept Therapeutics Incorporated total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corcept Therapeutics Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corcept Therapeutics Incorporated (2000–2025)
The table below shows the annual total liabilities of Corcept Therapeutics Incorporated from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $188.85 Million | +17.32% |
| 2024-12-31 | $160.96 Million | +40.20% |
| 2023-12-31 | $114.81 Million | +40.72% |
| 2022-12-31 | $81.59 Million | +70.15% |
| 2021-12-31 | $47.95 Million | -0.92% |
| 2020-12-31 | $48.39 Million | +17.66% |
| 2019-12-31 | $41.13 Million | +14.85% |
| 2018-12-31 | $35.81 Million | +21.11% |
| 2017-12-31 | $29.57 Million | +8.02% |
| 2016-12-31 | $27.37 Million | -18.14% |
| 2015-12-31 | $33.44 Million | -12.04% |
| 2014-12-31 | $38.02 Million | -9.61% |
| 2013-12-31 | $42.06 Million | +12.49% |
| 2012-12-31 | $37.39 Million | +643.91% |
| 2011-12-31 | $5.03 Million | +30.21% |
| 2010-12-31 | $3.86 Million | +59.57% |
| 2009-12-31 | $2.42 Million | -15.66% |
| 2008-12-31 | $2.87 Million | -4.72% |
| 2007-12-31 | $3.01 Million | -15.02% |
| 2006-12-31 | $3.54 Million | -0.59% |
| 2005-12-31 | $3.56 Million | +95.34% |
| 2004-12-31 | $1.82 Million | +18.62% |
| 2003-12-31 | $1.54 Million | -96.48% |
| 2002-12-31 | $43.73 Million | +2221.39% |
| 2001-12-31 | $1.88 Million | +51.69% |
| 2000-12-31 | $1.24 Million | -- |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more